Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib: is it clinically feasible?

Minerva Med

South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Saint Ladislaus Campus, Budapest, Hungary.

Published: December 2021

Download full-text PDF	Source
http://dx.doi.org/10.23736/S0026-4806.20.07050-0	DOI Listing

Publication Analysis

simultaneous effective

effective treatment

treatment critical

critical covid-19

covid-19 disease

disease newly

newly diagnosed

diagnosed high-risk

high-risk multiple

multiple myeloma

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!